Table 3.
AT levels and thrombin generation values in plasma from patients with and without PE at baseline and following treatment with enoxaparin (0.13 U/mL). Number with percentage or median and IQR values are reported. Mann-Whitney tests were performed to determine statistical significance between groups.
| P-value | |||
|---|---|---|---|
| Baseline | |||
| Rate AT<80% | 11 (20.4%) | 9 (19.6%) | 0.92 |
| AT (%) | 90 (77, 99) | 93 (78, 113) | 0.24 |
| Lag time (min) | 4.3 (3.8, 4.8) | 4.2 (3.7, 5.5) | 0.79 |
| Peak (nM) | 322 (272, 351)* | 286 (241, 335) | <0.05 |
| ttPeak (min) | 6.6 (5.8, 7.2) | 6.6 (6.0, 7.8) | 0.58 |
| ETP (nM) | 1524 (1313, 1728) | 1489 (1123, 1689) | 0.12 |
| Rate (nM/min) | 145 (112, 161)* | 118 (94, 150) | <0.05 |
| Enoxaparin | |||
| Anti FXa levels (IU/mL) | 0.13 (0.11, 0.14)* | 0.14 (0.12, 0.17) | <0.05 |
| Rate Anti FXa>0.13 | 24 (44%) | 26 (57%) | 0.23 |
| Delta Lagtime (%) | 7.9 (0, 10.6) | 6.6 (0, 13.1) | 0.74 |
| Delta Peak (%) | −20.7 (−29.7, −15.3)* | −30.6 (−37.8, −18.4) | <0.01 |
| Delta ttPeak (%) | 10.7 (6.4, 15.0)* | 13.0 (9.6, 20.4) | <0.05 |
| Delta ETP (%) | −13.2 (−18.5, −8.8) | −15.6 (−23.3, −11.3) | 0.10 |
| Delta Rate (%) | −34.2 (−43.7, −26.1 * | −45.4 (−55.3, −29.9) | <0.01 |